ES2196345T3 - Metodo para el pronostico del cancer prostatico. - Google Patents

Metodo para el pronostico del cancer prostatico.

Info

Publication number
ES2196345T3
ES2196345T3 ES97931170T ES97931170T ES2196345T3 ES 2196345 T3 ES2196345 T3 ES 2196345T3 ES 97931170 T ES97931170 T ES 97931170T ES 97931170 T ES97931170 T ES 97931170T ES 2196345 T3 ES2196345 T3 ES 2196345T3
Authority
ES
Spain
Prior art keywords
timosina
gene
timosine
seq
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97931170T
Other languages
English (en)
Inventor
Bruce R Zetter
Lere Bao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Application granted granted Critical
Publication of ES2196345T3 publication Critical patent/ES2196345T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5759—Thymosin or related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LOS PRESENTES INVENTORES HAN DESCUBIERTO QUE LOS HUMANOS TIENEN UN GEN QUE CODIFICA UNA NUEVA PROTEINA DE LA FAMILIA TIMOSINA - BE . ESTA NUEVA PROTEINA, DENOMINADA AQUI TIMOSINA BE 15, TIENE LA CAPACIDAD PARA FIJAR Y SECUESTRAR LA G ACTINA, COMO OTROS MIEMBROS DE LA FAMILIA DE LA TIMOSINA - BE PERO, AL CONTRARIO DE LO QUE SE SABE SOBRE OTROS MIEMBROS, REGULA TAMBIEN DIRECTAMENTE LA MOTILIDAD CELULAR EN LAS CELULAS DEL CARCINOMA PROSTATICO. SE AISLO UN ADNC DEL GEN DE LA TIMOSINA BE15 HUMANA (SEQ ID N°. 1) Y, DESPUES DE DEDUCIDA LA SECUENCIA DE AMINOACIDO (SEQ ID N°. 2). LOS PRESENTES INVENTORES HAN DEMOSTRADO QUE UNAS TRANSCRIPCIONES REFORZADAS (ARNM) Y LA EXPRESION DEL GEN DE LA TIMOSINA BE 15 EN CELULAS NO TESTICULARES GUARDA UNA ELEVADA CORRELACION CON EL ESTADO MORBOSO EN UNA SERIE DE CANCERES, COMO EL DE PROSTATA, PULMON, MELANOMA Y MAMA, PARTICULARMENTE LOS CANCERES METASTASICOS. EN CONSECUENCIA, EL DESCUBRIMIENTO DE NIVELES MAS ELEVADOS DE TRANSCRIPCION O PRODUCTO GENETICO EN TEJIDOS NO TESTICULARES PUEDE UTILIZARSE NO SOLO COMO DIAGNOSTICO, SINO TAMBIEN COMO PRONOSTICO DE DETERMINADOS TIPOS DE CANCERES.
ES97931170T 1996-06-17 1997-06-13 Metodo para el pronostico del cancer prostatico. Expired - Lifetime ES2196345T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/664,857 US5858681A (en) 1996-06-17 1996-06-17 Method for prognosis of prostate cancer

Publications (1)

Publication Number Publication Date
ES2196345T3 true ES2196345T3 (es) 2003-12-16

Family

ID=24667736

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97931170T Expired - Lifetime ES2196345T3 (es) 1996-06-17 1997-06-13 Metodo para el pronostico del cancer prostatico.

Country Status (11)

Country Link
US (2) US5858681A (es)
EP (2) EP0922223B1 (es)
JP (1) JP3642431B2 (es)
AT (2) ATE314652T1 (es)
AU (1) AU723144B2 (es)
CA (1) CA2257858A1 (es)
DE (2) DE69735020T2 (es)
DK (1) DK0922223T3 (es)
ES (1) ES2196345T3 (es)
PT (1) PT922223E (es)
WO (1) WO1997048982A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2379264A1 (en) 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
AU2002227077A1 (en) * 2000-12-01 2002-06-11 Duke University Zinc alpha-2-glycoprotein as indicator of cancer
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GR1004636B (el) * 2001-11-28 2004-07-14 ����������������������������������������}�����B�@�@����������@�� Προγνωσηατουακαρκινουαμεαχρησηατησαθυμοσινησαβ@α}τβ@bαα
US7776524B2 (en) 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
US7723496B2 (en) 2002-08-21 2010-05-25 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US20060105343A1 (en) * 2003-01-09 2006-05-18 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancer
WO2006026654A2 (en) 2004-08-27 2006-03-09 Exact Sciences Corporation Method for detecting a recombinant event
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
WO2007109881A1 (en) * 2006-03-24 2007-10-04 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof
US7449715B2 (en) * 2006-04-06 2008-11-11 Xerox Corporation Poly[bis(ethynyl)heteroacene]s and electronic devices generated therefrom
WO2008016111A1 (fr) 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Procédé permettant d'évaluer un cancer du poumon, dispositif d'évaluation d'un cancer du poumon, procédé d'évaluation d'un cancer du poumon, système d'évaluation d'un cancer du poumon, programme d'évaluation d'
WO2008075662A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
JP5746811B2 (ja) 2006-12-21 2015-07-08 味の素株式会社 大腸癌の評価方法、ならびに大腸癌評価装置、大腸癌評価方法、大腸癌評価システム、大腸癌評価プログラムおよび記録媒体
JP5754137B2 (ja) 2008-06-20 2015-07-29 味の素株式会社 前立腺癌の評価方法、前立腺癌評価装置、前立腺癌評価方法、前立腺癌評価プログラム、記録媒体、前立腺癌評価システム、および情報通信端末装置
GB2476789A (en) * 2009-11-10 2011-07-13 Gl Holdings Inc Bv Use of thymosin for treatment of type 2 diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248591A (en) * 1991-05-02 1993-09-28 Puente Fernando D Diagnosis of cancer and other proliferative disorders by analysis of prothymosin alpha expression

Also Published As

Publication number Publication date
JP2000513098A (ja) 2000-10-03
CA2257858A1 (en) 1997-12-24
WO1997048982A1 (en) 1997-12-24
PT922223E (pt) 2003-08-29
JP3642431B2 (ja) 2005-04-27
EP1270745A2 (en) 2003-01-02
EP0922223B1 (en) 2003-04-02
ATE314652T1 (de) 2006-01-15
EP1270745A3 (en) 2004-06-09
US5858681A (en) 1999-01-12
DE69735020T2 (de) 2006-07-27
AU723144B2 (en) 2000-08-17
ATE236406T1 (de) 2003-04-15
DK0922223T3 (da) 2003-07-14
DE69735020D1 (de) 2006-02-02
EP1270745B1 (en) 2005-12-28
DE69720471T2 (de) 2004-02-19
US6150117A (en) 2000-11-21
AU3487497A (en) 1998-01-07
EP0922223A1 (en) 1999-06-16
DE69720471D1 (de) 2003-05-08

Similar Documents

Publication Publication Date Title
ES2196345T3 (es) Metodo para el pronostico del cancer prostatico.
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
DE69737978D1 (de) Als 2f1 bezeichnetes rezeptorprotein
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
ATE237371T1 (de) Blasenmukosa mit zellen für die rekonstruktion von geweben
TR199701462T1 (xx) DNA Dizisi ve bununla kodlanm�� meme'ye �zel g���s kanseri proteini.
EP2377548A3 (en) Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
TR199801395A2 (xx) Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�.
ES2139012T3 (es) Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
ATE265220T1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
ES2126145T3 (es) Redireccionamiento de anticuerpos.
CO4410255A1 (es) Procedimiento para introducir acido nucleico en celulas eucarioticas superiores y medio para transfeccion
PT942999E (pt) Construcao armadilha de genes para a identificacao e isolamento de genes
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
Krause et al. UV radiation and cancer prevention: what is the evidence?
DE59911954D1 (de) Entladungslampe für dielektrisch behinderte entladungen mit verbesserter elektrodenkonfiguration
DE69737597D1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
DK0898708T3 (da) Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays
BR0014489B1 (pt) processo de produÇço de adenovÍrus, e, kit.
ES2088227T3 (es) Oligosacaridos.
Vandermeer Evaluation of c-KIT in ovarian surface epithelial cells and ovarian tumours.